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Interesterified palm olein lowers postprandial glucose-dependent insulinotropic polypeptide 
response in type 2 diabetes 
 
ABSTRACT 
Purpose: We aim to investigate the postprandial effects of palm olein (PO) and chemically 
interesterified palm olein (IPO) with different proportions of palmitic acid at the sn-2 position 
using high oleic sunflower oil (HOS) as control fat on concentrations of gut hormones, glucose 
homeostasis, satiety, lipid and inflammatory parameters in type 2 diabetic (T2D) subjects. 
Methods: Using a randomised double-blind crossover design, 21 (men = 6, women = 15) T2D 
subjects consumed test meals (3.65 MJ) consisting of a high fat muffin (containing 50 g test 
fats provided as PO, IPO or HOS) and a milkshake. Postprandial changes in gut hormones, 
glucose homeostasis, satiety, lipid and inflammatory parameters after meals were analysed. 
Some of the solid fractions of the IPO were removed and thus the fatty acid composition of the 
PO and IPO was not entirely equal (PO vs IPO: palmitate 39.8 vs 38.7; oleate 43.6 vs 45.1). 
PO, IPO and HOS contained 9.7, 38.9 and 0.2 g/100 g total fatty acids of palmitic acid at the 
sn-2 position, respectively. At 37 °C, IPO contained 4.2% SFC whereas PO and HOS were 
completely melted. Results: Our novel observation shows that the incremental area under curve 
(iAUC) 0-6 h of plasma GIP concentration was on average 16% lower following IPO meal 
compared with PO and HOS (P < 0.05) meals. Serum C-peptide concentrations exhibited a 
significant meal × gender interaction (P = 0.009). No differences between test meals were noted 
for other measurements. Conclusions: This study shows no adverse effect of interesterification 
on hormones associated with glucose homeostasis notably GLP-1 in T2D subjects. 
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